P

Pfizer

Makes cancer drugs, vaccines and other medicines

Senior Manager - Laboratory Design & Space Planning

Full-TimePosted on 10/23/2026Deadline 11/7/26
$124.4k - $207.4k/yr
Senior
Bachelor's, Master's
Cambridge, MA, USA+6 moreMore locations: Andover, MA, USA | Bothell, WA, USA | Chesterfield, MO, USA | Pearl River, NY, USA | Groton, CT, USA | San Diego, CA, USA
HybridHybrid work; approximately 25–30% domestic travel and global travel to R&D sites and regional offices as needed.
Architecture & Civil EngineeringArchitectural Design
No H1B Sponsorship

About the job

Requirements
  • A bachelor's degree in Architecture, Interior Design, Engineering, a scientific discipline, or a related built-environment field; equivalent professional qualification or experience is accepted in lieu.
  • At least 7 years of progressive experience in laboratory design and planning, space planning, or workplace/occupancy planning, including programming and design across multiple project phases and facility types.
  • Demonstrated expertise in pharmaceutical or biotechnology research environments and specialized laboratory types, including biology, chemistry, analytical and pharmaceutical sciences, process development, vivarium, clean room, and containment, as well as the scientific equipment, workflows, and operational, safety, and regulatory considerations that shape laboratory design.
  • Ability to translate user and scientific requirements into laboratory space programs, adjacency diagrams, test fits, and workflow-driven layouts, and to read and produce architectural drawings.
  • Proficiency with AutoCAD and Autodesk Construction Cloud, working knowledge of CAFM/IWMS and space-management platforms such as TRIRIGA, and proficiency with Microsoft Office, SharePoint, and Ariba.
  • Strong data-analysis and space-benchmarking skills, including cost estimating for laboratory builds, moves, and reconfigurations.
  • Knowledge of construction practices, applicable building codes, and laboratory environmental health and safety, life-safety, and egress requirements, and ability to apply current guidance when planning and rearranging laboratories.
  • Ability to lead cross-functional, multi-trade discussions; use sound judgment; work independently; and communicate, present, influence, and facilitate effectively.
  • Ability to analyze alternatives and technical and operational tradeoffs and manage multiple concurrent projects with competing priorities across a matrixed, global organization.
  • Ability to collaborate, listen, and adapt in ambiguous, evolving environments.
  • Breadth of diverse leadership experiences and capabilities, including influencing and collaborating with peers, developing and coaching others, and overseeing and guiding colleagues' work to achieve outcomes and business impact.
  • Ability to travel domestically approximately 25–30% and globally to R&D sites and regional offices as needed, and to work flexible hours across global time zones.
  • Candidates must be authorized to be employed in the United States by any employer; the role requires permanent work authorization in the United States.
Responsibilities
  • Engage R&D leaders and scientists to understand current and future portfolio-wide scientific requirements and translate them into practical laboratory, support, and associated office-space solutions.
  • Facilitate programming with scientists, laboratory operations, Engineering, Environmental Health and Safety, and Digital to capture workflows, equipment, headcount, capacity, adjacencies, and personnel and material flows; produce space programs, blocking-and-stacking concepts, and phase-appropriate planning narratives; and assess how automation and emerging technologies affect laboratory requirements.
  • Own and maintain laboratory planning and design standards across laboratories, hybrid workspaces, and shared support functions; drive their evolution and keep them current and shared with the Center of Excellence.
  • Integrate evidence-based insights, inclusive design, sustainability, well-being, safety, and operational feedback into global design standards, and help establish practical, safety-driven laboratory standards.
  • Identify opportunities for flexible, adaptable laboratory design as science priorities evolve, applying metrics and standards while customizing for colleague needs and intended use.
  • Balance generational, accessibility, and neurodivergent-design considerations with functionality, and balance technology and operational efficiency against cost to ensure efficient use of financial resources.
  • Support site, campus, and network master planning and strategic portfolio planning by forecasting laboratory and workplace demand, providing capacity, utilization, and feasibility analysis, and evaluating renovation, consolidation, expansion, and new-build options and their tradeoffs.
  • Maintain accurate space records in the CAFM/IWMS environment, such as TRIRIGA, and use data with approved analytics and AI-enabled tools to produce scenario-planning insights that inform capital investment and occupancy decisions.
  • Serve as the primary liaison among scientists, project teams, architects, engineers, and planners for laboratory space design and planning initiatives, and liaise with Global Workplace Design & Change Management and the Sustainability & Hospitality Center of Excellence.
  • Build relationships across workplace operations, laboratory operations, Engineering, Digital, Real Estate, capital planning, and project delivery teams, including external consultants; partner with each site's Environmental Health and Safety and Laboratory Instrument Services teams to confirm safety requirements and services needed when moving or populating labs.
  • Develop project scopes and support internal and external design and construction teams through design, construction, commissioning, start-up, and occupancy.
  • Use Autodesk Construction Cloud to test laboratory layouts, including corewalls, assets, and equipment; identify equipment-related utility, structural, environmental, containment, and digital requirements with Engineering and Environmental Health and Safety; and review design deliverables against approved programs.
  • Provide scope, assumptions, and risks to inform cost estimates, schedules, and investment planning.
  • Manage multiple concurrent small projects, typically under $50,000, on time, on budget, and safely, covering feasibility and test fits, proposals, logistics, work orders, Job Hazard Analysis, construction oversight, and multi-trade coordination; manage approved budgets, purchase orders, Ariba, and Statements of Work.
  • Estimate move and reconfiguration costs for proposed laboratory changes.
  • Bring innovative practices that keep the organization current with workplace-design and change-management trends, and embed sustainability, resilience, and operational continuity—including energy efficiency, waste reduction, eco-friendly materials, and colleague well-being—into laboratory recommendations.
  • Travel to R&D sites and periodically walk through office, laboratory, facility, and project environments.
Desired Qualifications
  • Proficiency with Revit, Bluebeam, building information modeling, and other industry-standard design and space-planning software.
  • Experience coordinating laboratory programming with containment, mechanical, electrical, and plumbing systems, casework, and equipment planning, and reviewing external consultant deliverables against approved programs.
  • Experience with master planning and strategic portfolio planning across multi-site or geographically dispersed portfolios.
  • Knowledge of sustainability frameworks relevant to laboratory and workplace design, including WELL, LEED, and BREEAM, and their application in corporate real estate.
  • Post-occupancy evaluation experience, including structured design, data collection, and findings synthesis.
  • Formal project- and change-management experience or certification.
  • A master's degree in architecture, engineering, facilities management, life sciences, or a related discipline, and/or relevant professional licensure or accreditation.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-3%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 27th, 2026
AT&T, Pfizer and Zoetis offer yields up to 5.8% with shares under $100

Rising interest rates and bond yields have made dividend stocks less appealing, pushing many lower and their yields higher. Three that trade below $100 are AT&T, Pfizer, and Zoetis, according to The Motley Fool. AT&T trades around $21, down about 16% this year, with a price-to-earnings (P/E) multiple of 11 against 23 for the S&P 500. It yields 5.3% after revenue grew more than 5% in the September quarter. Pfizer trades near $30 and yields 5.8%. Its forward P/E is 10, though its shares are down more than 30% over five years. Zoetis, down 37% this year, trades below $80 with a P/E of 13 and a yield of about 2.6%. Its payout ratio is around 34% of earnings, and it has 12 potential blockbusters in its pipeline.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.